Besponsa (Inotuzumab Ozogamicin) Approved for Deadly Blood Cancer

THURSDAY, Aug. 17, 2017 — The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL).
B-cell ALL is a rapidly growing cancer that occurs when…
Source: Topamax